"Only 15% of patients with squamous cell lung cancer – the second most common lung cancer – survive five years past diagnosis. Little is understood about how the deadly disease arises, preventing development of targeted therapies that could serve as a second line of defense once standard chemotherapy regimens fail.
"Published online in Cell Reports on June 19, Huntsman Cancer Institute investigators report that misregulation of two genes, sox2 and lkb1, drives squamous cell lung cancer in mice. The discovery uncovers new treatment strategies, and provides a clinically relevant mouse model in which to test them."
Editor's note: Some tumors have specific genetic mutations that can allow them to be treated with drugs known as targeted therapies. Studying mice with squamous cell lung cancer tumors, scientists have now discovered two new tumor mutations that open up the possibility for new drugs to be developed for humans. The mutations also indicate that some drugs that already exist for other cancers may be used to treat people with squamous cell lung cancer. More investigation is required before the results of these findings might translate to treatments for patients.